Commentary

Common Measures for National Institute of Mental Health Funded Research

Deanna M. Barch, Ian H. Gotlib, Robert M. Bilder, Daniel S. Pine, Jordan W. Smoller, C. Hendricks Brown, Wayne Huggins, Carol Hamilton, Adam Haim, and Gregory K. Farber

One of the most encouraging, but also the most challenging, aspects of current research on psychopathology is the diversity of measures used to assess constructs across research studies and programs. Clearly, this diversity reflects the creativity and generativity of our field and the continual growth of our science. At the same time, however, this diversity also makes data harmonization across studies difficult, if not sometimes impossible. The National Human Genome Research Institute recognized this conundrum in the field of genetics and started an initiative referred to as a consensus measures for Phenotypes and eXposures (PhenX) to identify and recommend a small number of measures for each of 21 broad research domains that could be used as common assessments to facilitate integration across genome-wide association studies (1–4). These measures are made available to the scientific community, at no cost, in the PhenX Toolkit (https://www.phenxtoolkit.org). Subsequently, the PhenX consensus process was used to identify measures in support of substance abuse and addiction (SAA) research, adding depth to the toolkit in this area. This project was funded by the National Institute on Drug Abuse (NIDA) with the participation of the National Institute on Alcohol Abuse and Alcoholism. Perhaps due to a growing awareness of the need to share data across studies to increase statistical power and study impact, a number of other common data element programs have been underway, including the Patient-Reported Outcomes Measurement Information System (5), the National Institutes of Health (NIH) Toolbox (6), the Neurological Quality of Life (7), the National Institute of Neurological Disorders and Stroke Common Data Elements program (8,9), and the NIH Common Data Elements program (http://www.nimh.nih.gov/cde/). The program staff at the National Institute of Mental Health (NIMH), as well as its funded researchers, have also recognized the challenges posed by a lack of common measures across studies. The NIMH has taken note of this recent emphasis on larger scale studies to address core questions about the mechanisms of psychopathology and recent attempts at data harmonization across studies of psychopathology that address similar issues. Accordingly, the NIMH felt that it was time to identify a brief, low-burden measures that NIMH-funded researchers could include in their studies to increase cross-study data compatibility. The goal of the current report is to briefly describe the genesis and development of the PhenX project, to outline the process that the Mental Health Research Panel used to select a set of common measures, to describe the measures themselves, and to outline the goals associated with including these measures in future studies.

PhenX

The goal of the original PhenX project, led by RTI International and funded by the National Human Genome Research Institute and the NIH Office of Behavioral and Social Sciences Research, was to identify and recommend well-established, low-burden, high-quality measures for use in large-scale genomic studies. The approach was to select up to 15 measures for each of 21 research domains and make them freely available to the research community via the PhenX Toolkit (https://www.phenxtoolkit.org). A 12-member steering committee decided the 21 domains to be addressed, including demographics, anthropometrics, environmental exposures, speech and hearing, psychiatric, and psychosocial, and set forth criteria for selecting measures (https://www.phenxtoolkit.org/index.php?pageLink=browse) (1). For each domain, a working group of six to nine experts was convened to identify measures using a rigorous consensus process that includes a series of conference calls, in-person meetings, and outreach to the research community (10). The measures selected by the original 21 working groups were completed in 2011 and resulted in 295 measures being released in the PhenX Toolkit.

PhenX Measures For Substance Abuse and Addiction Research

NIDA subsequently provided funding for a project to add depth to the toolkit in support of SAA research. The impetus for this project relates to the fact that there is very low commonality in the measures used across studies of abuse and addiction (11). This project, which added 45 measures to the PhenX Toolkit, included a core collection and six specialty collections of SAA measures. The SAA core collection consists of two tiers: tier 1 and tier 2. The Core: Tier 1 collection was designed to take respondents approximately 8 to 10 minutes to complete and includes basic demographic measures and assessments of substance use. Core: Tier 2 is expected to take approximately 27 to 46 minutes and includes expanded demographic information, substance use, psychiatric disorders screening, peer use of substances, and social network information.

NIDA’s expectations for the inclusion of these core and specialty measures in studies funded by this agency are described in a published notice (http://grants.nih.gov/grants/guide/notice-files/NOT-DA-12-008.html):

“Core: Tier 1: The measures in this collection are deemed relevant and essential to all areas of addiction science. NIDA grantees/applicants conducting human-subject studies are
strongly encouraged to incorporate, at a minimum, the Core:
Tier 1 measures.

Core: Tier 2: The measures in this collection are deemed
relevant to all areas of addiction science. Because Tier-2
measures are considered more burdensome and specialized
than the Tier-1 measures, NIDA grantees/applicants conducting
human-subject studies are strongly encouraged to incorpore
them whenever possible and appropriate.

Specialty: The measures in this collection are deemed
relevant and essential within specific areas of addiction
science. NIDA grantees/applicants conducting human-
subject studies in the specified areas of science are strongly
couraged to incorporate the Specialty measures.”

Since the SAA collections of measures were released in the
PhenX Toolkit in the spring of 2012, both NIDA and NIAA have
couraged use of PhenX measures in numerous funding
opportunity announcements.

NIMH Initiatives

An even broader emphasis in NIMH on cross-study harmoni-
zation began to emerge when NIMH encouraged eight differ-
ent groups of researchers studying the prodrome of psychosis
to combine their efforts into the North American Prodrome
Longitudinal Study. The North American Prodrome Longitudi-
nal Study was originally eight independently designed and
funded projects (12) but suffered from the challenges associ-
ated with the relatively low conversion rates within any one
relatively small sample, which could be bolstered by aggregat-
ing across samples. This data harmonization effort, while
successful in many ways (13–18), illustrated the difficulties of
combining data across studies using different measures to
assess similar constructs. Thus, in 2013, the NIMH, in
partnership with RTI International, convened the Mental
Health Research Panel (MHRP) to guide the selection of a
core set of measures for mental health related research, similar
to the Core: Tier 1 and Core: Tier 2 measures selected by the
NIDA SAA scientific panel. Based on calls in the National
Research Action Plan (http://www.whitehouse.gov/sites/default/
files/uploads/nrap_for_oe_on_mental_health_august_2013.pdf),
the NIMH has convened specialty working groups to
identify and recommend measures focused on specific mental
health related research questions (e.g., suicide, posttraumatic
stress disorder). In addition, the NIMH has supported data
integration approaches though the establishment of the National
Database for Autism Research (19), a platform that is expanding
to include data from Research Domain Criteria (RDoC) focused
projects.

The MHRP recognized the tradeoffs associated with
recommending that all NIMH-funded studies include a set of
core measures. On the positive side, the inclusion of at least a
small set of common measures will clearly facilitate cross-
study replication and will allow the aggregation of data across
studies into larger data sets that should permit statistically
stronger tests of hypotheses or the testing of novel hypoth-
theses that could not be addressed in any single study. On the
negative side, any requirement that investigators include a
specific set of measures has to be balanced with the important
need for researchers to choose and include measures of the
specific constructs of interest to their particular studies. As
such, some could view the emphasis on common data
elements as hindering scientific innovation, though clearly
both are important for forward progress. For these reasons,
the MHRP felt that the recommended NIMH Core: Tier 1 and
Core: Tier 2 measures needed to be very brief and low burden,
ensuring that investigators would have ample time to include
the additional measures they feel are important to addressing
their specific aims. Consequently, we selected a set of
measures designed to be primarily self-report and/or easy to
administer and to take less than 15 minutes to complete (see
Table 1 and the PhenX website, www.phenxtoolkit.org/, for a
more detailed description of criteria and measure attributes).
The MHRP also separately identified measures that would be
appropriate for use in studies of adults/adolescents versus
studies of children. Like NIDA, NIMH suggests that the Core:
Tier 1 measures are relevant and essential to all areas of
mental health research, and all NIMH grantees/applicants
conducting human research will be strongly encouraged to
include Core: Tier 1 measures in their studies. While the Core:
Tier 2 measures are also relevant to all areas of mental health
research, they are slightly more burdensome and specialized
than the Core: Tier 1 measures. Thus, NIMH grantees/applic-
ants conducting research with human subjects are strongly
couraged to incorporate Core: Tier 2 measures when feasible and appropriate.

NIMH Core: Tier 1

As shown in Table 1, several of the recommended NIMH Core:
Tier 1 measures are focused on demographic and
socioeconomic-related measures. We recognize that many, if
not most, researchers already collect such measures in their
studies. Importantly, however, the wording of the assessments
and the ways in which they are coded differ significantly
across studies. Thus, adopting a common framework would
facilitate cross-study data aggregation and address questions
related to the effects of factors such as age, race, and
socioeconomic status (SES) on relevant outcomes. The goal
of including child-reported parental education attainment
(when the child is old enough to provide such reports) is to
gather information on the role of developmental SES, given
the growing body of data showing that developmental SES
may have a major impact on both psychosocial and biological
outcomes (20–23). In addition, the MHRP suggested that
investigators include brief self-report measures of broad
psychopathology and impairment for both child and adult
studies. Some of these measures were not previously included
in the PhenX, but we felt that their inclusion was critical for
studies of mental health outcomes to provide a broad and
basic assessment of these domains.

For a broad psychopathology assessment for children, we
recommended including the Strengths and Difficulties Quest-

www.sobp.org/journal

Table 1 and the PhenX website, www.phenxtoolkit.org/, for a
more detailed description of criteria and measure attributes).
about including this measure, given the recent emphasis by NIMH on the RDoC initiative and the potential perception that recommending a DSM-5 oriented measure would be seen as counter to this initiative. Nevertheless, most experts agree that DSM-5 and RDoC provide complementary approaches to assessment. As such, it is important to have a common, but brief, symptom-based measure in studies focused on mental health, even for studies that were generated primarily from an RDoC-based framework. We should also note, however, that the MHRP felt strongly that the question designed to assess suicidal ideation on this measures (question VI) was clearly not adequate for the assessment of the full range of suicide-related ideation; it felt that it may be better labeled self-harm. Those researchers specifically interested in a comprehensive assessment of suicide should see the forthcoming recommendations of the suicide working group.

For a measure of impairment in children, we recommended the use of the 13-item Columbia Impairment Scale (30), a brief validated measure of function in four areas: interpersonal relationships, psychopathology, school or work function, and leisure time. We recognize that an ideal measure would complete separate indicators of psychopathology from indicators of function but also realize that this is difficult, if not impossible, to accomplish in children. The Columbia Impairment Scale has both parent- and child-report versions. For adults, we recommended the 12-item self-report version of the World Health Organization Disability Assessment Schedule 2.0 (31–33).

**NIMH Core: Tier 2**

Given the broad range of research questions addressed in NIMH-funded studies, the MHRP found it challenging to identify additional measures that were relevant to all NIMH-funded, human-subjects research. However, three additional areas appear relevant to the vast majority of mental health related studies: assessments of substance use, life events, and perceived stress. Existing research clearly documents significant comorbidity of substance use difficulties in individuals who are experiencing mental health related difficulties. Thus, the MHRP recommended including the brief SAA Core: Tier 1 assessments of tobacco, alcohol, and substance use (11) in the NIMH Core: Tier 2, with separate measures for adults and adolescents. The PhenX Toolkit already includes self/parent report measures of life events for children [Adverse Life Events Scale (34,35)] and adults [Traumatic Life Events Questionnaire (36,37)], each of which had originally been selected by the social environments working group. We are aware that there is evidence that more intensive interview-based assessments of life events have incremental validity, but we felt that it was not feasible to recommend such measures in this context. For perceived stress, the PhenX Toolkit already includes the 10-item Perceived Stress Scale (38,39), selected by the psychosocial working group of experts who consulted broadly. The MHRP recognized that perceptions of stress can be influenced by current mood and other factors but felt that the predictive utility of assessing perceived

---

**Table 1. Mental Health Research Measures**

<table>
<thead>
<tr>
<th>Measure</th>
<th>Description of Protocol</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Current Age</td>
<td>The respondent is asked for his/her date of birth in MM/DD/YYYY format. If the respondent does not know his/her date of birth, there is an alternative question to determine his/her age.</td>
</tr>
<tr>
<td>2. Race</td>
<td>The respondent is asked to indicate one or more categories that describe what race he or she considers himself or herself to be. The question meets the Office of Management and Budget standards for capturing data on race.</td>
</tr>
<tr>
<td>3. Ethnicity</td>
<td>The respondent is asked whether they consider themselves to be Hispanic or Latino. An additional question captures the specific Hispanic origin. The question meets the Office of Management and Budget standards for capturing data on ethnicity.</td>
</tr>
<tr>
<td>4. Gender</td>
<td>The respondent is asked for his/her self-conception of being male or female.</td>
</tr>
<tr>
<td>5. Current Marital Status</td>
<td>The respondent is asked for his/her current marital status.</td>
</tr>
<tr>
<td>6. Current Educational Attainment</td>
<td>The respondent is asked for his/her highest educational attainment at the current time.</td>
</tr>
<tr>
<td>7. Annual Family Income</td>
<td>The respondent is asked for his/her total income from all sources in the last calendar year. Respondents who don’t know or refuse to answer the first annual family income question are asked a series of bracketing questions to obtain the approximate amount.</td>
</tr>
<tr>
<td>8. Child-Reported Parent Educational Attainment</td>
<td>The respondent is asked for the highest level of education achieved by his/her residential parents (i.e., while growing up).</td>
</tr>
<tr>
<td>9. Impairment</td>
<td>Adults: The World Health Organization Disability Assessment Schedule 2.0 12-question self-administered questionnaire is a generic assessment instrument for health and disability that covers six domains: cognition, mobility, self-care, getting along, life activities, and participation. Items are rated from none, mild, moderate, severe, to extreme or cannot do, indicating difficulty over the past month.</td>
</tr>
<tr>
<td>10. Broad Psychopathology (proposed new measure)</td>
<td>Adults: The DSM-5 Level 1 Cross-Cutting Symptom Measure is a 23-item self-report or informant-rated questionnaire that assesses 13 domains that are important across psychiatric diagnoses. Each item inquires about how much (or how often) the individual has been bothered by the specific symptom during the past 2 weeks.</td>
</tr>
</tbody>
</table>

Core: Tier 1 measures are considered to be essential to all areas of mental health research and should be included in all National Institute of Mental Health funded human subjects research.
stress was sufficient to mitigate against these concerns. For children, we could not identify a validated measure of self-reported perceived stress appropriate for pediatric populations or parent reports of their child’s perception of stress. Thus, developing a measure that assesses such constructs appears to be an important task for future work.

Time Frames
One of the challenges in the use of the measures recommended for NIMH Core: Tier 1 and Core: Tier 2 is that the recommended time frames for assessment vary across measures. For example, whereas the World Health Organization Disability Assessment Schedule 2.0 asks about the last 30 days, the DSM-5 Level 1 Cross-Cutting measure inquires about the last 2 weeks and the Strengths and Difficulties Questionnaire asks about the last 6 months. Further, the appropriate time frame may vary for different types of studies (e.g., cross-sectional, longitudinal, treatment-focused). To preserve comparability across existing studies, the MHRP recommended that the default be to use the time frame recommended by the developers of the measures for all cross-sectional studies and for the baseline assessments for longitudinal and treatment studies, but the MHRP recognized that other time frames might be justified for projects in which the default time frame might be inappropriate or confuse participants. If these measures are used at subsequent time points in longitudinal or treatment studies, it is further recognized that researchers may need to modify the time frames in ways that are appropriate for their particular study design given the time intervals between assessments.

Opportunities and Challenges of Data Harmonization
As with most things, there are opportunities and challenges associated with a move toward even a small subset of common data elements. On the opportunities side, the use of common measures of broad psychopathology and impairment, as well as demographic factors, will support the aggregation of data sets of various types (e.g., structural and functional imaging, behavioral measures, etc.) that might then have greater power to detect, for example, interactions between demographic factors and psychopathology/impairment or between different aspects of psychopathology. Further, data aggregation will allow greater power in exploratory studies; the challenges of multiple comparison correction for many statistical tests can often preclude the generation of informative results that can guide future research. On the challenges side, sometimes a push toward common data elements can encourage investigators to use less than optimal measures [e.g., PhenX recommendation of digit span as a measure of working memory, which is not a state-of-the-art measure of all aspects of working memory [40]]. For these reasons, the MHRP focused on keeping the measures recommended for Core: Tier 1 and Core: Tier 2 very brief and focused on elements with the clearest clinical significance (e.g., psychopathology, impairment, substance use, demographics), leaving investigators to select what they believe are the state-of-the-art measures for the specific constructs of interest in their studies. We also recognize that there may be domains in which there are large and consistent effect sizes, and thus data aggregation may not be necessary to generate clinically meaningful and impactful data. At the same time, it should be recognized that greater consistency of measurements and increased ability to combine, compare, and/or contrast findings across studies may yield benefits beyond those that can be anticipated at the time of study.

Conclusions
The large-scale aggregation of data, beyond those feasibly collected by individual investigators, is a crucial engine for the discovery and validation of advances in mental health research. Perhaps the most striking proof of concept of this has come from genomic studies in which widespread data sharing, through the international Psychiatric Genomics Consortium, has transformed psychiatric genetics. Previous single investigator/group studies were limited by the challenges of multiple statistical tests with relatively small Ns, and thus data aggregation has taken the field from having virtually no established risk loci in 2008 to nearly 200 confirmed loci today. This has included more than 100 common risk variants for schizophrenia alone (41). In fact, the availability of common data elements beyond simply diagnostic categories has become a rate-limiting step for further discovery.

We expect the PhenX Toolkit will be an important platform for enabling such discoveries in mental health, clinical neuroscience, and genetic research by facilitating data harmonization across studies. Certainly, there are numerous other opportunities to identify common measures that can be used across studies relevant to mental health, but relatively few of these measures would be relevant to all mental health related studies being funded by the NIMH. Instead, the MHRP felt that the next step was to examine such opportunities for common data elements at the level of subgroups of studies with shared goals and constructs, perhaps at the level of RDoC domains or constructs. As the first wave of RDoC-focused research comes to fruition, the validity of potential measures will become more apparent and the time may then be ripe for efforts focused on identifying common date elements for assessing RDoC constructs. An additional major opportunity created by increased harmonization of measurements across NIMH projects is the capacity to develop shared knowledge bases, which ultimately can be mined to address questions impossible on the scale of any single study.

Acknowledgments and Disclosures
Deanna Barch is funded by the National Institute of Mental Health (NIMH) (R01MH66031; R01MH084840; R01MH090788; R01MH098845-S), the National Institutes of Health Blueprint (U54MH091657), and National Alliance for Research on Schizophrenia and Depression. Deanna Barch consults for Pfizer, Amgen, and Roche and has a contract to analyze imaging data for Pfizer. Dr. Gotlib is funded by NIMH (MH074849 and MH101495). Dr. Bilder is funded by NIMH (MH101478). Dr. Bilder has received honoraria or consulting fees from EnVivo, Forum Pharmaceuticals, Lumosity, SnapChat, Takeda-Lundbeck, and ThinkNow, Inc. Dr. Smoller is funded by NIMH (MH094614) and is the Tepper Family Massachusetts General Hospital Research Scholar. Dr. Brown is funded by NIMH (MH050885). Dr. Huggins is funded by the National Human Genome Research Institute (U41 HG007050). Dr. Hamilton is funded by the National Human Genome Research Institute (U41 HG007050). Dr. Smoller is an
unpaid member of the Scientific Advisory Board of PsyBrain, Inc. Dr. Pine, Dr. Haim, and Dr. Farber report no biomedical financial interests or potential conflicts of interest.

**Article Information**

From the Departments of Psychology, Psychiatry, and Radiology (DMB), Washington University, St. Louis, Missouri; Department of Psychology (HH), Stanford University, Stanford, California; Departments of Psychiatry and Biobehavioral Sciences and Psychology (RMF), University of California at Los Angeles, Los Angeles, California; National Institute of Mental Health (DSP), Intramural Research Program, Bethesda, Maryland; Psychiatric and Neurodevelopmental Genetics Unit (JWS), Center for Human Genetic Research, and Department of Psychiatry (JWS), Massachusetts General Hospital; and Stanley Center for Psychiatric Research (JWS), Broad Institute, Boston, Massachusetts; Department of Psychiatry (CHB), Northwestern University, Chicago, Illinois; RTI International (WH, CH), Research Triangle Park, Durham, North Carolina; and Office of Clinical Research (AH) and Office of Technology Development and Coordination (GKF), National Institute of Mental Health, Bethesda, Maryland.

Address correspondence to Deanna M. Barch, Ph.D., Washington University, Departments of Psychology, Psychiatry and Radiology; Box 1125, One Brooksings Drive, St. Louis, MO 63130; E-mail: dbarch@wustl.
edu.

Received Jun 3, 2015; revised Jul 13, 2015; accepted Jul 15, 2015.

**References**


